Results 91 to 100 of about 4,268 (199)

Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals

Objective: Large inter-individual variability in the pharmacokinetics of rilpivirine and cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) therapy.
Davide Moschese, Sara Soloperto, Dario Cattaneo, Spinello Antinori, Cristina Gervasoni, Maria Vittoria Cossu, Andrea Gori, Giuliano Rizzardini, Antonio D’Avolio, Andrea Giacomelli   +9 more
core   +1 more source

Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025

Eurosurveillance
Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation.
Valentina Mazzotta
doaj   +1 more source

Cabotegravir

Australian Prescriber, 2022
openaire   +3 more sources

Author Correction: Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection [PDF]

Correction to "Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV ...
Prasher, Alka, Kovarova, Martina, Young, Isabella C., Montgomery, Stephanie A., Wong-Sam, Andres, Cottrell, Mackenzie L., Garcίa-Lerma, J. Gerardo, Mrotz, Victoria, Kashuba, Angela D. M., Dobard, Charles W., Seixas, Josilene Nascimento, Maturavongsadit, Panita, Massud, Ivana, Thorson, Allison, Garcia, J. Victor, Benhabbour, S. Rahima, Dinh, Chuong, Edwards, Tiancheng, Sykes, Craig, Pallerla, Aryani, Heneine, Walid, Shrivastava, Roopali, Schauer, Amanda, Mitchell, James, De la Cruz, Gabriela   +24 more
core   +1 more source

Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting

Fifty-eight people with HIV switched to long-acting cabotegravir and rilpivirine in a real-world clinic setting had higher discontinuation rates because of virologic failure, side effects, or nonadherence compared to clinical trials.
Payne, Shannon, Brar, Indira, Yared, Nicholas, Gudipati, Smitha   +3 more
core   +1 more source

Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084

Journal of the International AIDS Society
Introduction HPTN 084 found that long‐acting cabotegravir (CAB‐LA) was well‐tolerated and significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (F/TDF).
Mark A. Marzinke, Brett Hanscom, Daniel Haines, Kimberly K. Scarsi, Yaw Agyei, Estelle Piwowar‐Manning, Craig W. Hendrix, Ryann Gollings, Scott Rose, Carrie Mathew, Ravindre Panchia, Elizabeth Spooner, Nishanta Singh, Peter Bock, Alex R. Rinehart, Susan L. Ford, James F. Rooney, Lydia Soto‐Torres, Myron S. Cohen, Mina C. Hosseinipour, Sinead Delany‐Moretlwe, HPTN 084 Study Team   +21 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

First case of HIV seroconversion with integrase resistance mutations on long-acting cabotegravir for prevention in routine care [PDF]

BACKGROUND: Long-acting cabotegravir (CAB-LA) is highly effective for HIV prevention, but delayed HIV diagnoses and integrase strand transfer inhibitor (INSTI) resistance were observed in trials.
et al.,, Koss, Catherine A, Patel, Rupa R   +2 more
core   +1 more source

Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States

Journal of the International AIDS Society
Introduction Long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) represents a breakthrough in HIV treatment. However, understanding how to optimize real‐world service delivery and user experiences among people with HIV (PWH) remains limited ...
Xavier A. Erguera, Mollie B. Smith, Priyasha Pareek, Alicia Dawdani, Kaylin V. Dance, Ryan S. Walker, Janet Grochowski, Jon Oskarsson, Matthew D. Hickey, Mallory O. Johnson, John Sauceda, Jose I. Gutierrez Jr., Elizabeth T. Montgomery, Jonathan A. Colasanti, Lauren F. Collins, Moira C. McNulty, Kimberly A. Koester, Katerina A. Christopoulos   +17 more
doaj   +1 more source

Oral pre-exposure prophylaxis implementation in South Africa: a case study of USAID-supported programs

Frontiers in Reproductive Health
Since the introduction of oral pre-exposure prophylaxis (PrEP) in 2016, countries have successfully scaled-up PrEP to populations at risk of HIV acquisition, including key populations, serodiscordant couples and pregnant women.
Jerome Wendoh Milimu, Lauren Parmley, Mahlodi Matjeng, Mathata Madibane, Mandisi Mabika, Jacques Livingston, Joseph Lawrence, Orapeleng Motlhaoleng, Hasina Subedar, Rethabile Tsekoa, Zandile Mthembu   +10 more
doaj   +1 more source